ACAD - NASDAQ
ACADIA Pharmaceuticals Inc.
$21.43
+1.6%ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
At a Glance
Live SnapshotNo Dividend Yield Data
ACAD has not reported any dividend yield values in the available annual periods.
No Dividend Payout Ratio Data
ACAD has not reported any dividend payout ratio values in the available annual periods.
No Net Dividends Paid Data
ACAD has not reported any net dividends paid values in the available annual periods.
ACADIA Pharmaceuticals Inc. Dividend History
ACAD Dividend Payment History
| Declaration | Ex-Date | Payment Date | Dividend | Adjusted | Frequency | Growth |
|---|---|---|---|---|---|---|
| No dividend payment history available | ||||||
ACADIA Pharmaceuticals Inc. Payout Ratio Analysis
Dividend Sustainability Analysis
Payout Ratio
Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.
FCF Payout Ratio
Excellent FCF coverage. Dividend is well-supported by actual cash generation with ample room for increases and business reinvestment.
Sustainability
Dividend sustainability questionable. Monitor closely for signs of stress. Consider whether yield justifies the risk.
Related Guides
Continue your ACAD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.